NCT04667949View on ClinicalTrials.gov

Study of Efficacy and Safety of Fingolimod (Gilenya) 0.5 mg in Chinese Patients With Relapsing Multiple Sclerosis (RMS) Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

98

Participants

Timeline

Start Date

February 20, 2021

Primary Completion Date

March 25, 2025

Study Completion Date

March 25, 2025

Conditions
Relapsing Multiple Sclerosis (RMS)
Interventions
DRUG

Fingolimod 0.5mg

Subjects received fingolimod 0.5mg capsule QD up to month 24

Trial Locations (13)

100000

Novartis Investigative Site, Beijing

100028

Novartis Investigative Site, Beijing

130021

Novartis Investigative Site, Changchun

200040

Novartis Investigative Site, Shanghai

215004

Novartis Investigative Site, Suzhou

325000

Novartis Investigative Site, Wenzhou

430030

Novartis Investigative Site, Wuhan

450052

Novartis Investigative Site, Zhengzhou

510260

Novartis Investigative Site, Guangzhou

510623

Novartis Investigative Site, Guangzhou

510630

Novartis Investigative Site, Guangzhou

610041

Novartis Investigative Site, Chengdu

065001

Novartis Investigative Site, Beijing

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY